(Q34023059)

English

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

phase II clinical trial

0 references

aggressive fibromatosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Isabelle Ray-Coquard

6

object named as

I Ray-Coquard

0 references

2

object named as

A Le Cesne

0 references

15

object named as

J-Y Blay

0 references

author name string

N Penel

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

B N Bui

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D Perol

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

E G Brain

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C Guillemet

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C Chevreau

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D Cupissol

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Chabaud

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Jimenez

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

F Duffaud

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Piperno-Neumann

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

L Mignot

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

9 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

452-457

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Biology of gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Imatinib as a possible cause of severe rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Roadmap for developing and validating therapeutically relevant genomic classifiers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Optimizing Treatment of Desmoid Tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ341

21 January 2018

Identifiers

10.1093/ANNONC/MDQ341

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34023059&oldid=1981504393"